Patient management by Neoral C(2) monitoring: an international consensus statement.
about
Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory MyopathiesPharmGKB summary: cyclosporine and tacrolimus pathwaysSignificance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trialPre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [coCyclosporin therapeutic drug monitoring--an established service revisited.Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patientsCurrent and future immunosuppressive strategies in renal transplantation.Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome.Optimizing the use of cyclosporin in allogeneic stem cell transplantation.Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.Update on immunosuppressive drugs used in solid-organ transplantation and their nutrition implications.Therapeutic drug monitoring in pediatric renal transplantation.Cyclosporine use in hematopoietic stem cell transplantation: pharmacokinetic approach.Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient.Utility of C-2 (Cyclosporine) monitoring in postrenal transplant patients: A study in the Indian population.MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behçet's disease patients.Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients.C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.Liver transplantation without steroid induction in HIV-infected patients.Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosisTwo-hour post-dose cyclosporine monitoring does not fit all in kidney transplantationThe Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients
P2860
Q26798023-3E40A98A-5353-4738-8FC2-C6E08F9DF071Q33989902-0B1F8D42-94DF-49C8-8D7F-5DC8320F7752Q34324240-9BA0E6E5-38EB-4A00-9D73-4F3E1FB49568Q35107728-68714E6A-AA51-4AB2-8D10-9FC88AB6C182Q35759193-8F86B90B-44AF-41EC-9C77-848FA6220FA1Q35827273-97B7D370-6CF4-4270-BE1A-14F23D4C73C4Q35906315-70C7FF08-A9A1-4E48-954E-7E78532158DAQ35980234-0BDE7BC8-EBDF-4F8D-87D5-D957CC5C8B19Q36036364-E2BD2718-837B-482B-AF8B-8AFE04BAEDF7Q36153584-9A80291D-E3ED-49C5-990B-6076CCD94BF1Q36496718-41060D72-C085-423F-A7C2-457250E9F348Q36623201-865CA148-0732-465E-A891-1A72E2FF9C1AQ36955927-547D9345-10A7-4931-8F60-E4C5F1CED0DAQ38206952-AB37950B-F9F3-45B8-A556-B4C2C4053DA7Q38562065-CF8A3ABC-D087-4292-B587-7AFD72F7A816Q42175356-A49939AC-048A-4ABA-B83D-CA78B2A0B982Q42928160-ABD151A1-F9AE-47BE-913E-7E6BE785B9A6Q43106920-89D97B3D-E63E-4C86-AEB9-343C46916A3CQ44738359-4EA096A3-3D9C-4815-8E4A-ADFC2E015DDEQ45197127-344B2DBD-E641-4E9C-B154-E64B432721BFQ45289826-83CD391C-4361-4CA5-B16C-6AB09C94DBF0Q46475776-A627E707-B31F-4C43-B072-3D1CD4BE73B8Q46485596-7E59755A-DD1D-413D-A6AB-C423A36C1368Q46630204-1BA607BD-9A38-48C7-8829-949232FA2D61Q46920548-77DB89AD-57A9-4202-9AB1-16812C7265A1Q50580595-9A870354-EFA3-4720-B42C-D5F25DD1C3A6Q51083518-5B829AE9-55DE-4408-821E-D26E89F117B0Q51384101-37D6C890-E997-4EDD-B430-94208E0806D9Q53242992-886440F8-AA93-4874-A3CA-ECDDDF0497B6Q57212294-A31F3F5E-648E-4A36-941E-E7FE70F7E075Q57703033-D7D25ACF-A6F6-44F9-A446-C51074D0CB05Q58869670-8850AE7F-3723-4EC4-A923-94ED301D9E80
P2860
Patient management by Neoral C(2) monitoring: an international consensus statement.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Patient management by Neoral C
@nl
Patient management by Neoral C(2) monitoring: an international consensus statement.
@ast
Patient management by Neoral C(2) monitoring: an international consensus statement.
@en
type
label
Patient management by Neoral C
@nl
Patient management by Neoral C(2) monitoring: an international consensus statement.
@ast
Patient management by Neoral C(2) monitoring: an international consensus statement.
@en
prefLabel
Patient management by Neoral C
@nl
Patient management by Neoral C(2) monitoring: an international consensus statement.
@ast
Patient management by Neoral C(2) monitoring: an international consensus statement.
@en
P2093
P1433
P1476
Patient management by Neoral C(2) monitoring: an international consensus statement.
@en
P2093
Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group
Eric Thervet
Kazuharu Uchida
P356
10.1097/00007890-200205151-00003
P433
P577
2002-05-01T00:00:00Z